



Immediate Action

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, February 25, 2019

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

Effective Date:

Monday, February 25, 2019



	Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
	0487SP	Atovaquone, Serum/Plasma		•	•	•			•	
	52020B	Chlorzoxazone Confirmation, Blood		•	•	•			•	
Ī	52020FL	Chlorzoxazone Confirmation, Fluid								٠
	52020SP	Chlorzoxazone Confirmation, Serum/Plasma		•	•	•			•	
	52020TI	Chlorzoxazone Confirmation, Tissue								٠
	52020U	Chlorzoxazone Confirmation, Urine								•
	1255B	Chlorzoxazone, Blood		•	•	•			•	
	1255SP	Chlorzoxazone, Serum/Plasma		•	•	•			•	
	1255U	Chlorzoxazone, Urine								•
	54455B	DUID/DRE Primidone and PEMA Confirmation, Blood		•	•	•			•	
	2136B	Fosphenytoin as Metabolite, Blood	٠	•	•				•	
	2136SP	Fosphenytoin as Metabolite, Serum/Plasma	٠	•	•	•			•	
	2456SP	Isotretinoin, Serum/Plasma	•	•	•	•			•	
	52069B	Mephenytoin and Metabolite Confirmation, Blood								•
	52069FL	Mephenytoin and Metabolite Confirmation, Fluid								•
	52069SP	Mephenytoin and Metabolite Confirmation, Serum/Plasma								•
	52069TI	Mephenytoin and Metabolite Confirmation, Tissue								•
	2620SP	Mephenytoin and Metabolite, Serum/Plasma								•
	52070B	Mephobarbital and Metabolite Confirmation, Blood								•
	52070FL	Mephobarbital and Metabolite Confirmation, Fluid								•
	52070SP	Mephobarbital and Metabolite Confirmation, Serum/Plasma								•
	52070TI	Mephobarbital and Metabolite Confirmation, Tissue								•
	2630B	Mephobarbital and Metabolite, Blood								٠
	2630SP	Mephobarbital and Metabolite, Serum/Plasma								•
	52078B	Methsuximide as Metabolite Confirmation, Blood		•	•				•	
	52078FL	Methsuximide as Metabolite Confirmation, Fluid		•	•					
	52078SP	Methsuximide as Metabolite Confirmation, Serum/Plasma		•	•	•			•	
	5644SP	Methsuximide as Metabolite Confirmation, Serum/Plasma								•

Effective Date:

Monday, February 25, 2019



Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52078TI	Methsuximide as Metabolite Confirmation, Tissue		•						
9336SP	Methsuximide as Metabolite Screen, Serum/Plasma								•
2950B	Methsuximide as Metabolite, Blood		•	•				•	
2950SP	Methsuximide as Metabolite, Serum/Plasma		•	•	•			•	
3380B	Pemoline, Blood								•
3380SP	Pemoline, Serum/Plasma								•
3582SP	Phenobarbital - Total/Unbound/Bound, Serum/Plasma	•	•	•		•		•	
3581SP	Phenobarbital - Unbound, Serum/Plasma	•	•	•		•			
9416B	Phenobarbital Screen, Blood		•	•				•	
9416SP	Phenobarbital Screen, Serum/Plasma		•	•	•			•	
3580B	Phenobarbital, Blood		•	•				•	
3580SP	Phenobarbital, Serum/Plasma		•	•	•			•	
3707B	Phenylethylmalonamide, Blood		•	•	•			•	
3707SP	Phenylethylmalonamide, Serum/Plasma		•	•				•	
3751SP	Phenytoin - Total, Serum/Plasma								٠
54105B	Phenytoin Confirmation (DUID/DRE), Blood		•	•				•	
52105B	Phenytoin Confirmation, Blood		•	•				•	
5673B	Phenytoin Confirmation, Blood								•
52105FL	Phenytoin Confirmation, Fluid		•	•					
5673FL	Phenytoin Confirmation, Fluid								•
52105SF	Phenytoin Confirmation, Serum/Plasma		•	•	•			•	
5673SP	Phenytoin Confirmation, Serum/Plasma								•
52105TI	Phenytoin Confirmation, Tissue		•						
52105U	Phenytoin Confirmation, Urine		•	•					
9239B	Phenytoin Screen, Blood								•
9239FL	Phenytoin Screen, Fluid								•
9239SP	Phenytoin Screen, Serum/Plasma								•
3743B	Phenytoin, Blood		•	•				•	
3743FL	Phenytoin, Fluid		•	•					
3743SP	Phenytoin, Serum/Plasma		•	•	•			•	
3743TI	Phenytoin, Tissue		•						

Effective Date:

Monday, February 25, 2019



Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52106B	Primidone, Phenobarbital and PEMA Confirmation, Blood		•	•	•			•	
52106FL	Primidone, Phenobarbital and PEMA Confirmation, Fluid		•	•					
52106SP	Primidone, Phenobarbital and PEMA Confirmation, Serum/Plasma		•	•	•			•	
52106TI	Primidone, Phenobarbital and PEMA Confirmation, Tissue		•						
3900B	Primidone, Phenobarbital and PEMA, Blood		•	•	•			•	
3900FL	Primidone, Phenobarbital and PEMA, Fluid		•	•					
3900SP	Primidone, Phenobarbital and PEMA, Serum/Plasma		•	•	•			•	
3901SP	Primidone, Serum/Plasma		•		•			•	
5962U	Synthetic Cannabinoid Metabolites Confirmation (Qualitative) - Expanded (2019 Scope), Urine	•				•			
9562U	Synthetic Cannabinoid Metabolites Screen - Expanded (2019 Scope), Urine (Forensic)	•				•			
4283U	Synthetic Cannabinoid Metabolites- Expanded (Qualitative) (2019 Scope), Urine	•				•			
4759SP	Valproic Acid - Unbound and Total, Serum/Plasma	•	•	•	•	•		•	
52162B	Valproic Acid Confirmation, Blood (CSA)		•	•				•	
52162FL	Valproic Acid Confirmation, Fluid (CSA)		•	•					
52162SP	Valproic Acid Confirmation, Serum/Plasma (CSA)		•	•				•	
52162TI	Valproic Acid Confirmation, Tissue (CSA)		•						
52162U	Valproic Acid Confirmation, Urine (CSA)		•	•					
9552B	Valproic Acid Screen (Add-On), Blood (Forensic) (CSA)		•	•				•	
9552FL	Valproic Acid Screen (Add-On), Fluid (Forensic) (CSA)		•	•					
9552SP	Valproic Acid Screen (Add-On), Serum/Plasma (Forensic) (CSA)		•	•				•	
9552TI	Valproic Acid Screen (Add-On), Tissue (Forensic) (CSA)		•						
9552U	Valproic Acid Screen (Add-On), Urine (Forensic) (CSA)		•	•					
4757B	Valproic Acid, Blood		•	•				•	
4757FL	Valproic Acid, Fluid		•	•					
4757SP	Valproic Acid, Serum/Plasma		•	•				•	
4760SP	Valproic Acid, Serum/Plasma								•



Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
4757TI	Valproic Acid, Tissue		•						
4761SP	Valproic Acid, Unbound, Serum/Plasma	•	•	•		٠			
4757U	Valproic Acid, Urine		•	•					



Test Changes

0487SP Atovaquone, S	Serum/Plasma
Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]
Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Atovaquone
Compound Name	Units Reference Comment

	Units	Reference Comment
Atovaquone	mcg/mL	Failure to administer Atovaquone with food may result
		in lower Atovaquone plasma concentrations.
		The recommended therapeutic range in plasma is
		14 +/- 7 mcg/mL for treatment of malaria.

52020B Chlorzoxazone Confirmation, Blood

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80369)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)



Test Changes

Scope of Analysis: LC-MS/MS (80369): Chlorzoxazone Method (CPT Code)

Compound Name	Units	Reference Comment
Chlorzoxazone	mcg/mL	Healthy men given a single oral dose of 750 mg attained an average peak plasma concentration of 36 +/- 2 mcg/mL at approximately 38 minutes. The blood to plasma ratio is not known.
52020SP Chlorzoxazon	e Confirmation, Serum/P	Plasma
Summary of Changes:	Specimen Requirements Specimen Requirements Stability was changed. Reference Comment wa Methods/CPT Codes we	s were changed. s (Specimen Container) were changed. as changed. ere changed [LC-MS/MS (80369)]
Specimen Requirements:	1 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preser	rvative-free)
Light Protection:	Not Required	
Special Handling: Rejection Criteria:	Serum: Collect sample in Plasma: Collect sample Promptly centrifuge and using approved guideline Polymer gel separation t	n Red top tube in Lavender top tube (EDTA) or Pink top tube. separate Serum or Plasma into a plastic screw capped vial es. tube (SST or PST).
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 14 c Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(LC-MS/MS (80369): Chl	day(s) (s) orzoxazone
Compound Name	Units	Reference Comment
Chlorzoxazone	mcg/mL	Healthy men given a single oral dose of 750 mg attained an average peak plasma concentration of 36 +/- 2 mcg/mL at approximately 38 minutes.
1255B Chlorzoxazon	e, Blood	
Summary of Changes:	Specimen Requirements Specimen Requirements Stability was changed. Reference Comment wa	s were changed. s (Specimen Container) were changed. as changed.



Specimen Requirements:	1 mL Blood			
Transport Temperature:	Refrigerated			
Specimen Container:	Lavender top tube (EDTA)			
Light Protection:	Not Required			
Special Handling:	None			
Rejection Criteria:	None			
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s) LC-MS/MS (80369): Chlorzoxa:	zone		
Compound Name	Units	Reference Comment		
Chlorzoxazone	mcg/mL	Healthy men given a single oral dose of 750 mg attained an average peak plasma concentration of 36 +/- 2 mcg/mL at approximately 38 minutes. The blood to plasma ratio is not known.		
1255SP Chlorzoxazone	e, Serum/Plasma			
Summary of Changes:	Summary of Changes: Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80369)]			
Specimen Requirements:	1 mL Serum or Plasma			
Transport Temperature:	Refrigerated			
Specimen Container:	Plastic container (preservative-	free)		
Light Protection:	Not Required			
Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines				
Rejection Criteria:	Polymer gel separation tube (S	ST or PST).		
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)			
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80369): Chlorzoxa	zone		



Compound Name	Units	Reference Comment			
Chlorzoxazone	mcg/mL	Healthy men given a single oral dose of 750 mg attained an average peak plasma concentration of 36 +/- 2 mcg/mL at approximately 38 minutes.			
4455B DUID/DRE Prii	midone and PEMA Confirmat	tion, Blood			
Summary of Changes:	Specimen Requirements wer Specimen Requirements (Sp Stability was changed. Reference Comment was cha Methods/CPT Codes were ch	re changed. ecimen Container) were changed. anged. nanged [LC-MS/MS (80184, 80188)]			
Specimen Requirements:	1 mL Blood				
Transport Temperature:	Refrigerated				
Specimen Container:	Lavender top tube (EDTA)				
Light Protection:	Not Required				
Special Handling:	None				
Rejection Criteria:	None				
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s) LC-MS/MS (80184, 80188): F	s) Primidone, Phenylethylmalonamide (PEMA)			
Compound Name	Units	Reference Comment			
Primidone	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 5-10 mcg/mL. The blood to plasma ratio is approximately 1.			
Phenylethylmalonamide (PEMA)	mcg/mL	Following a single oral dose of 400 mg Primidone to elderly men: 12 +/- 3 mcg PEMA/mL serum. The blood to plasma ratio is unknown.			
136B Fosphenytoin	as Metabolite, Blood				
Summary of Changes:	Test Name was changed. Specimen Requirements wer Specimen Requirements (Sp Reference Comment was cha Methods/CPT Codes were ch	re changed. ecimen Container) were changed. anged. nanged [LC-MS/MS (80185)]			



Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80185): Phenytoin

Compound Name	Units	Reference Comment
Phenytoin	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with phenytoin: 10-20 mcg/mL The blood to plasma ratio is approximately 0.5.

2136SP Fosphenytoin as Metabolite, Serum/Plasma

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80185)]
Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 3 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80185): Phenytoin

Compound Name	Units	Reference Comment
Phenytoin	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with phenytoin: 10-20 mcg/mL

2456SP Isotretinoin, Serum/Plasma





Test Changes

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]		
Specimen Requirements:	1 mL Serum or Plasma		
Transport Temperature:	Refrigerated		
Specimen Container:	Plastic container (preserv	Plastic container (preservative-free)	
Light Protection:	Yes		
Special Handling: Rejection Criteria:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a light protected plastic screw capped vial using approved guidelines. Not received Light Protected. Polymer gel separation tube (SST or PST).		
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 14 da Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s) LC-MS/MS (80375): Isotro	ay(s)) etinoin	
	Unite	Peference Comment	
Isotretinoin	ng/mL	Patients taking 30 to 50 mg daily oral isotretinoin for 3 months had steady state plasma isotretinoin concentrations ranging from 91 to 291 ng/mL and an elimination half-life ranging from 10 to 37 hours. Compounds known to interfere with this substance:	

9-cis, 13-cis-retinoic acid.

Summary of Changes:	Specimen Requirements were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80339)]	
Specimen Requirements:	1 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Normethsuximide	



Test Changes

Compound Name	Units	Reference Comment	
Normethsuximide	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with methsuximide: 10-40 mcg/mL The blood to plasma ratio is not known.	
52078FL Methsuximide	as Metabolite Confirmation,	Fluid	
Summary of Changes:	Specimen Requirements wer Methods/CPT Codes were ch	re changed. nanged [LC-MS/MS (80339)]	
Specimen Requirements:	2 mL Fluid		
Transport Temperature:	Refrigerated		
Specimen Container:	Plastic container (preservativ	e-free)	
Light Protection:	Not Required		
Special Handling:	None		
Rejection Criteria:	None		
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Normethsuximide		
52078SP Methsuximide	as Metabolite Confirmation,	Serum/Plasma	
Summary of Changes:	Specimen Requirements wer Stability was changed. Reference Comment was cha Methods/CPT Codes were ch	re changed. anged. nanged [LC-MS/MS (80339)]	
Specimen Requirements:	1 mL Serum or Plasma		
Transport Temperature:	Refrigerated		
Specimen Container:	Plastic container (preservative-free)		
Light Protection:	Not Required		
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.		
Rejection Criteria:	Polymer gel separation tube (SST or PST).		
Stability:	Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)		
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Normeth	nsuximide	
Compound Name	Units	Reference Comment	
Normethsuximide	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with methsuximide: 10-40 mcg/mL	

52078TI Methsuximide as Metabolite Confirmation, Tissue



Test Changes

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80339)]		
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Normethsuximide		
2950B Methsuximide	e as Metabolite, Blood		
Summary of Changes:	Specimen Requirements were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80339)]		
Specimen Requirements:	1 mL Blood		
Transport Temperature:	Refrigerated		
Specimen Container:	Lavender top tube (EDTA)		
Light Protection:	Not Required		
Special Handling:	None		
Rejection Criteria:	None		
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Normethsuximide		
Compound Name	Units	Reference Comment	
Normethsuximide	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with methsuximide: 10-40 mcg/mL The blood to plasma ratio is not known.	
2950SP Methsuximide			
	as Metabolite, Serum/Plasma		
Summary of Changes:	as Metabolite, Serum/Plasma Specimen Requirements were of Stability was changed. Reference Comment was chang Methods/CPT Codes were char	changed. ged. nged [LC-MS/MS (80339)]	
Summary of Changes:	as Metabolite, Serum/Plasma Specimen Requirements were of Stability was changed. Reference Comment was chang Methods/CPT Codes were char 1 mL Serum or Plasma	changed. ged. nged [LC-MS/MS (80339)]	
Summary of Changes: Specimen Requirements: Transport Temperature:	as Metabolite, Serum/Plasma Specimen Requirements were of Stability was changed. Reference Comment was chang Methods/CPT Codes were char 1 mL Serum or Plasma Refrigerated	changed. ged. nged [LC-MS/MS (80339)]	
Summary of Changes: Specimen Requirements: Transport Temperature: Specimen Container:	as Metabolite, Serum/Plasma Specimen Requirements were of Stability was changed. Reference Comment was chang Methods/CPT Codes were char 1 mL Serum or Plasma Refrigerated Plastic container (preservative-f	changed. ged. nged [LC-MS/MS (80339)]	
Summary of Changes: Specimen Requirements: Transport Temperature: Specimen Container: Light Protection:	as Metabolite, Serum/Plasma Specimen Requirements were of Stability was changed. Reference Comment was chang Methods/CPT Codes were char 1 mL Serum or Plasma Refrigerated Plastic container (preservative-f Not Required	changed. ged. nged [LC-MS/MS (80339)]	

Rejection Criteria: Polymer gel separation tube (SST or PST).

Stability: Room Temperature: 7 day(s) Refrigerated: 14 day(s)

Frozen (-20 °C): 14 day(s) e of Analysis: LC-MS/MS (80339): Normethsuximide

Scope of Analysis: Method (CPT Code)



Compound Name	Units	Reference Comment
Normethsuximide	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with methsuximide: 10-40 mcg/mL
3582SP Phenobarbita	ll - Total/Unbound/Bound, Seru	ım/Plasma
Summary of Changes	 Test Name was changed. Specimen Requirements were Scope of Analysis was change Phenobarbital - Unbound was Reference Comment was cha Methods/CPT Codes were cha (80184)] Phenobarbital - Free was rem 	e changed. ed. added. nged. anged [LC-MS/MS (80184), LC-MS/MS oved.
Specimen Requirements	2 mL Serum or Plasma	
Transport Temperature	Refrigerated	
Specimen Container	Plastic container (preservative	e-free)
Light Protection	Not Required	
Special Handling	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.	
Rejection Criteria	Polymer gel separation tube (SST or PST).
Scope of Analysis Method (CPT Code)	: LC-MS/MS (80184): Phenoba) LC-MS/MS (80184): Phenoba	rbital - Unbound rbital - Total, Phenobarbital - Bound
Compound Name	Units	Reference Comment
Phenobarbital - Unbound	mcg/mL	Approximately 54% of phenobarbital is unbound to serum proteins (free) at therapeutic concentrations.
Phenobarbital - Total	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 10-40 mcg/mL.
Phenobarbital - Bound	mcg/mL	Phenobarbital - Bound is calculated by subtracting Phenobarbital - Unbound from Phenobarbital - Total.
3581SP Phenobarbita	I - Unbound, Serum/Plasma	
Summary of Changes	 Test Name was changed. Specimen Requirements were Specimen Requirements (Specimen Requirements (Specimen de Scope of Analysis was change Phenobarbital - Unbound was Methods/CPT Codes were cha Phenobarbital - Free was rem 	e changed. ecial Handling) were changed. ed. added. anged [LC-MS/MS (80184)] oved.





Test Changes

Specimen Requirements:	2 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-free)	
Light Protection:	Not Required	
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.	
Rejection Criteria:	Polymer gel separation tube (SST or PST).	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80184): Phenobark	bital - Unbound
Compound Name	Units	Reference Comment
Phenobarbital - Unbound	mcg/mL	Approximately 54% of phenobarbital is unbound to serum proteins (free) at therapeutic concentrations.
9416B Phenobarbital	Screen, Blood	
Summary of Changes:	Specimen Requirements were Specimen Requirements (Spec Reference Comment was chan Methods/CPT Codes were char	changed. imen Container) were changed. ged. nged [LC-MS/MS (80307)]
Specimen Requirements:	2 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80307): Phenobarbital	
Compound Name	Units	Reference Comment
Phenobarbital	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 10-40 mcg/mL. The blood to plasma ratio is approximately 0.8.

9416SP Phenobarbital Screen, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed.
	Stability was changed.
	Reference Comment was changed.
	Methods/CPT Codes were changed [LC-MS/MS (80307)]

Test Updates



Test Changes

Scope of Analysis: Method (CPT Code)	Frozen (-20 °C): 14 day(s) LC-MS/MS (80307): Phenobarbital
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s)
, Stability:	Poor Tomporature: 14 day(c)
Rejection Criteria:	Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Polymer gel separation tube (SST or PST).
Special Handling:	Serum: Collect sample in Red top tube
Light Protection:	Not Required
pecimen Container:	Plastic container (preservative-free)
nsport Temperature:	Refrigerated
imen Requirements:	2 mL Serum or Plasma
i r	men Requirements: hsport Temperature: pecimen Container: Light Protection: Special Handling: Rejection Criteria: Stability:

Compound Name	Units	Reference Comment
Phenobarbital	mcg/mL	Recommended serum concentration range during
		anticonvulsant therapy with primidone: 10-40 mcg/mL.

3580B Phenobarbital, Blood

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80184)]

Phenobarbital	mcg/mL	Recommended serum concentration range during
Compound Name	Units	Reference Comment
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80184): Phenobarl	pital
Rejection Criteria:	None	
Special Handling:	None	
Light Protection:	Not Required	
Specimen Container:	Lavender top tube (EDTA)	
Transport Temperature:	Refrigerated	
Specimen Requirements:	1 mL Blood	

Recommended serum concentration range during anticonvulsant therapy with primidone: 10-40 mcg/mL. The blood to plasma ratio is approximately 0.8.

3580SP Phenobarbital, Serum/Plasma

Test Updates



Test Changes

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80184)]
Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80184): Phenobarbital

Compound Name	Units	Reference Comment
Phenobarbital	mcg/mL	Recommended serum concentration range during
		anticonvulsant therapy with primidone: 10-40 mcg/mL.

3707B Phenylethylmalonamide, Blood

Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80339)]		Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80339)]
---	--	---------------------	---

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Phenylethylmalonamide (PEMA)



Test Changes

Compound Name	Units	Reference Comment
Phenylethylmalonamide (PEMA)	mcg/mL	Following a single oral dose of 400 mg Primidone to elderly men: 12 +/- 3 mcg PEMA/mL serum. The blood to plasma ratio is unknown.
3707SP Phenylethylma	alonamide, Serum/Plasma	
Summary of Changes:	Specimen Requirements were Reference Comment was char Methods/CPT Codes were cha	changed. nged. nged [LC-MS/MS (80339)]
Specimen Requirements:	1 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative	free)
Light Protection:	Not Required	
Special Handling:	Serum: Collect sample in Red Plasma: Collect sample in Lave Promptly centrifuge and separa using approved guidelines.	top tube ender top tube (EDTA) or Pink top tube. ate Serum or Plasma into a plastic screw capped vial
Rejection Criteria:	Polymer gel separation tube (S	ST or PST).
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Phenyleth	ylmalonamide (PEMA)
Compound Name	Units	Reference Comment
Phenylethylmalonamide (PEMA)	mcg/mL	Following a single oral dose of 400 mg Primidone to elderly men: 12 +/- 3 mcg PEMA/mL serum.
54105B Phenytoin Co	nfirmation (DUID/DRE), Blood	
Summary of Changes:	Specimen Requirements were Specimen Requirements (Spec Reference Comment was char Methods/CPT Codes were cha	changed. cimen Container) were changed. iged. nged [LC-MS/MS (80185)]
Specimen Requirements:	1 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80185): Phenytoin	



Test Changes

Compound Name	Units	Reference Comment
Phenytoin	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with phenytoin: 10-20 mcg/mL The blood to plasma ratio is approximately 0.5.
52105B Phenytoin Cor	nfirmation, Blood	
Summary of Changes:	Specimen Requirements were of Specimen Requirements (Spec Reference Comment was chang Methods/CPT Codes were char	changed. imen Container) were changed. ged. nged [LC-MS/MS (80185)]
Specimen Requirements:	1 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80185): Phenytoin	
Compound Name	Units	Reference Comment
Phenytoin	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with phenytoin: 10-20 mcg/mL The blood to plasma ratio is approximately 0.5.
52105FL Phenytoin Cor	nfirmation, Fluid	
Summary of Changes:	Specimen Requirements were of Methods/CPT Codes were char	changed. nged [LC-MS/MS (80185)]
Specimen Requirements:	2 mL Fluid	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-	free)
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80185): Phenytoin	
52105SP Phenytoin Cor	nfirmation. Serum/Plasma	

Test Updates



Test Changes

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80185)]		
Specimen Requirements:	1 mL Serum or Plasma		
Transport Temperature:	Refrigerated		
Specimen Container:	Plastic container (preservative-free)		
Light Protection:	Not Required		
Special Handling: Rejection Criteria:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Polymer gel separation tube (SST or PST).		
Scope of Analysis:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 3 month(s)		
Method (CPT Code)			
Compound Name	Units	Reference Comment	
Phenytoin	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with phenytoin: 10-20 mcg/mL	

52105TI Phenytoin Confirmation, Tissue

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (80185)]

Scope of Analysis: LC-MS/MS (80185): Phenytoin Method (CPT Code)

52105U Phenytoin Confirmation, Urine

Summary of Changes:	Specimen Requirements were changed.
	Specimen Requirements (Specimen Container) were changed.
	Methods/CPT Codes were changed [LC-MS/MS (80185)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None



Test Changes

Scope of Analysis: LC-MS/MS (80185): Phenytoin Method (CPT Code)

3743B Phenytoin, Blo	ood		
Summary of Changes: Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80185)]		changed. imen Container) were changed. ged. iged [LC-MS/MS (80185)]	
Specimen Requirements:	1 ml Blood		
Transport Temperature:	Refrigerated		
Specimen Container:	Lavender top tube (FDTA)		
Light Protection:	Not Required		
Special Handling:	None		
Rejection Criteria:	None		
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80185): Phenytoin		
Compound Name	Units	Reference Comment	
Phenytoin	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with phenytoin: 10-20 mcg/mL The blood to plasma ratio is approximately 0.5.	
3743FL Phenytoin, Flu	id		
Summary of Changes:	Specimen Requirements were of Methods/CPT Codes were char	changed. nged [LC-MS/MS (80185)]	
Specimen Requirements:	2 mL Fluid		
Transport Temperature:	Refrigerated		
Specimen Container:	Plastic container (preservative-free)		
Light Protection:	Not Required		
Special Handling:	None		
Rejection Criteria:	None		
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80185): Phenytoin		
3743SP Phenytoin, Sei	rum/Plasma		
Summary of Changes:	Specimen Requirements were of Stability was changed. Reference Comment was changed	changed. ged.	

Methods/CPT Codes were changed [LC-MS/MS (80185)]

Test Updates



Test Changes

	l luite	Deference Comment	
Method (CPT Code)			
Scope of Analysis:	LC-MS/MS (80185): Phenytoin		
	Frozen (-20 °C): 3 month(s)		
,	Refrigerated: 14 day(s)		
Stability:	Room Temperature: 14 day(s)		
Rejection Criteria:	Polymer gel separation tube (S	ST or PST).	
	Promptly centrifuge and separa	te Serum or Plasma into a plastic screw capped vial	
	Plasma: Collect sample in Lave	nder top tube (EDTA) or Pink top tube.	
Special Handling:	Serum: Collect sample in Red t	op tube	
Light Protection:	Not Required		
Specifier Container.	Flastic container (preservative-	nee)	
Specimen Container:	Plastic container (preservative-	(ree)	
Transport Temperature:	Refrigerated		
Specimen Requirements:	1 mL Serum or Plasma		

Compound Name	Units	Reference Comment
Phenytoin	mcg/mL	Recommended serum concentration range during
		anticonvulsant therapy with phenytoin: 10-20 mcg/mL

3743TI Phenytoin, Tissue

Summary of Changes: Methods/CPT Codes were changed [LC-MS/MS (80185)]

Scope of Analysis:	LC-MS/MS (80185): Phenytoin
Method (CPT Code)	

52106B Primidone, Phenobarbital and PEMA Confirmation, Blood

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80184, 80188)]
	Methods/CPT Codes were changed [LC-MS/MS (80184, 80188)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)
Scope of Analysis:	LC-MS/MS (80184, 80188): Primidone, Phenobarbital, Phenylethylmalonamide



Compound Name	Units	Reference Comment	
Primidone	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 5-10 mcg/mL. The blood to plasma ratio is approximately 1.	
Phenobarbital	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 10-40 mcg/mL. The blood to plasma ratio is approximately 0.8.	
Phenylethylmalonamide (PEMA)	mcg/mL	Following a single oral dose of 400 mg Primidone to elderly men: 12 +/- 3 mcg PEMA/mL serum. The blood to plasma ratio is unknown.	
52106FL Primidone, Ph	enobarbital and PEMA C	onfirmation, Fluid	
Summary of Changes:	Specimen Requirements Methods/CPT Codes wer	were changed. e changed [LC-MS/MS (80184, 80188)]	
Specimen Requirements:	2 mL Fluid		
Transport Temperature:	Refrigerated		
Specimen Container:	- Plastic container (preservative-free)		
Light Protection:	Not Required		
Special Handling:	None		
Rejection Criteria:	None		
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80184, 80188): Primidone, Phenobarbital, Phenylethylmalonamide (PEMA)		
52106SP Primidone, Ph	enobarbital and PEMA C	onfirmation, Serum/Plasma	
Summary of Changes:	Specimen Requirements Stability was changed. Reference Comment was Methods/CPT Codes wer	were changed. s changed. e changed [LC-MS/MS (80184, 80188)]	
Specimen Requirements:	1 mL Serum or Plasma		
Transport Temperature:	Refrigerated		
Specimen Container:	Plastic container (preserv	vative-free)	
Light Protection:	Not Required		
Special Handling:	Serum: Collect sample in Plasma: Collect sample in Promptly centrifuge and s using approved guideline	Red top tube n Lavender top tube (EDTA) or Pink top tube. separate Serum or Plasma into a plastic screw capped vial s.	
Rejection Criteria:	Polymer gel separation tu	ube (SST or PST).	



Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s) LC-MS/MS (80184, 80188): Pri (PEMA)	midone, Phenobarbital, Phenylethylmalonamide
Compound Name	Units	Reference Comment
Primidone	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 5-10 mcg/mL.
Phenobarbital	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 10-40 mcg/mL.
Phenylethylmalonamide (PEMA)	mcg/mL	Following a single oral dose of 400 mg Primidone to elderly men: 12 +/- 3 mcg PEMA/mL serum.
52106TI Primidone, Ph	enobarbital and PEMA Confirn	nation, Tissue
Summary of Changes:	Methods/CPT Codes were char	nged [LC-MS/MS (80184, 80188)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80184, 80188): Primidone, Phenobarbital, Phenylethylmalonamide (PEMA)	
3900B Primidone, Ph	enobarbital and PEMA, Blood	
Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80184, 80188)]	
Specimen Requirements:	1 mL Blood	
Transport Temperature:	Refrigerated	
Specimen Container:	Lavender top tube (EDTA)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria: Stability:	None Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80184, 80188): Pri (PEMA)	midone, Phenobarbital, Phenylethylmalonamide



Compound Name	Units	Reference Comment
Primidone	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 5-10 mcg/mL. The blood to plasma ratio is approximately 1.
Phenobarbital	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 10-40 mcg/mL. The blood to plasma ratio is approximately 0.8.
Phenylethylmalonamide (PEMA)	mcg/mL	Following a single oral dose of 400 mg Primidone to elderly men: 12 +/- 3 mcg PEMA/mL serum. The blood to plasma ratio is unknown.
3900FL Primidone, Ph	enobarbital and PEMA, F	luid
Summary of Changes:	Specimen Requirements Methods/CPT Codes were	were changed. e changed [LC-MS/MS (80184, 80188)]
Specimen Requirements:	2 mL Fluid	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-free)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80184, 80188): Primidone, Phenobarbital, Phenylethylmalonamide (PEMA)	
3900SP Primidone, Ph	enobarbital and PEMA, S	erum/Plasma
Summary of Changes:	Specimen Requirements Stability was changed. Reference Comment was Methods/CPT Codes were	were changed. changed. e changed [LC-MS/MS (80184, 80188)]
Specimen Requirements:	1 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preserv	ative-free)
Light Protection:	Not Required	
Special Handling:	Serum: Collect sample in Plasma: Collect sample in Promptly centrifuge and s using approved guidelines	Red top tube a Lavender top tube (EDTA) or Pink top tube. eparate Serum or Plasma into a plastic screw capped vial s.
Rejection Criteria:	Polymer gel separation tu	be (SST or PST).



Test Changes

Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s) LC-MS/MS (80184, 80188): Prin (PEMA)	midone, Phenobarbital, Phenylethylmalonamide
Compound Name	Units	Reference Comment
Primidone	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 5-10 mcg/mL.
Phenobarbital	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 10-40 mcg/mL.
Phenylethylmalonamide (PEMA)	mcg/mL	Following a single oral dose of 400 mg Primidone to elderly men: 12 +/- 3 mcg PEMA/mL serum.
3901SP Primidone, Se	rum/Plasma	
Summary of Changes:	Stability was changed. Reference Comment was chang Methods/CPT Codes were char	ged. nged [LC-MS/MS (80188)]
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s) LC-MS/MS (80188): Primidone	
Compound Name	Units	Reference Comment
Primidone	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with primidone: 5-10 mcg/mL.
5962U Synthetic Can	nabinoid Metabolites Confirma	tion (Qualitative) - Expanded (2019 Scope), Urine
Summary of Changes:	Test Name was changed. Scope of Analysis was changed 5-fluoro-PICA 3,3-dimethylbutar FUBICA 3,3-dimethylbutanoic a carboxy-CUMYL-BINACA, 4-ca CHMINACA 3,3-dimethylbutano	I. noic acid, CHMINACA-3-methylbutanoic acid, cid, 5-fluoro-PIC-ACID, CHMIC-ACID, 4- rboxy-AMB-PINACA, 5-fluoro-PINAC-ACID, nic acid, 5-fluoro-PINACA 3-methylbutanoic

acid, 5-fluoro-PINACA 3,3-dimethylbutanoic acid, FUBINACA 3-

methylbutanoic acid, FUBINACA 3,3-dimethylbutanoic acid, 4-carboxy-NA-PIM and FUBIC-ACID were added.

JWH-018 N-pentanoic acid, UR-144 N-pentanoic acid, AKB48 N-pentanoic acid, AB-FUBINACA oxobutanoic acid, AB-CHMINACA 3-methyl-butanoic



Test Changes		
	acid, PB-22 3-Carboxyin Carboxyindole, ADB-PIN acid, ADBICA N-pentano 5F-AMB 3-methyl-butanoic AMB 3-methyl-butanoic acid were removed.	dole, 5-Fluoro-PB-22 3-Carboxyindole, BB-22 3- IACA N-pentanoic acid, AB-PINACA N-pentanoic nic acid, ADB-CHMINACA 3,3-dimethyl-butanoic acid, pic acid, 5F-ADB 3,3-dimethyl-butanoic acid, FUB- acid and MDMB-FUBINACA 3,3-dimethyl-butanoic
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80352): 4-carboxy-NA-PIM, FUBIC-ACID, 5-fluoro-PICA 3,3- dimethylbutanoic acid, CHMINACA-3-methylbutanoic acid, FUBICA 3,3- dimethylbutanoic acid, 5-fluoro-PIC-ACID, CHMIC-ACID, 4-carboxy-CUMYL- BINACA, 4-carboxy-AMB-PINACA, 5-fluoro-PINAC-ACID, CHMINACA 3,3- dimethylbutanoic acid, 5-fluoro-PINACA 3-methylbutanoic acid, 5-fluoro-PINACA 3,3- dimethylbutanoic acid, FUBINACA 3-methylbutanoic acid, FUBINACA 3,3- dimethylbutanoic acid, FUBINACA 3-methylbutanoic acid, FUBINACA 3,3-	
Compound Name	Units	Reference Comment
4-carboxy-NA-PIM	ng/mL	4-carboxy-NA-PIM (JWH-018 N-pentanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): NA-PIM (JWH-18).
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
FUBIC-ACID	ng/mL	FUBIC-ACID (FUB-PB-22-Carboxyindole) is a known or presumed metabolite of the following synthetic cannabinoid(s): ADMB-FUBICA (ADB-FUBICA); NA-FUBIM (FUB-JWH-18); NA-FUBIC (FDU-PB-22); MDMB-FUBICA; MMB-FUBICA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
5-fluoro-PICA 3,3- dimethylbutanoic acid	ng/mL	5-fluoro-PICA 3,3-dimethylbutanoic acid is a known or presumed metabolite of the following synthetic cannabinoid(s): 5-fluoro-MDMB-PICA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
CHMINACA-3-methylbutanc acid	ic ng/mL	CHMINACA-3-methylbutanoic acid (AB-CHMINACA 3-methyl-butanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): AMB-CHMINACA (AB-CHMINACA); MMB-CHMINACA (MA-CHMINACA).
		It may also be a metabolite of other synthetic cannabinoids with similar structures.



Compound Name	Units	Reference Comment
FUBICA 3,3-dimethylbutanoic acid	ng/mL	FUBICA 3,3-dimethylbutanoic acid is a known or presumed metabolite of the following synthetic cannabinoid(s): ADMB-FUBICA (ADB-FUBICA); MDMB-FUBICA (5-fluoro AMB).
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
5-fluoro-PIC-ACID	ng/mL	5-fluoro-PIC-ACID (5-Fluoro-PB-22 3-Carboxyindole) is a known or presumed metabolite of the following synthetic cannabinoid(s): 5-fluoro-MDMB-PICA; 5-fluoro-NA-PIC (NM-221).
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
CHMIC-ACID	ng/mL	CHMIC-ACID (BB-22 3-Carboxyindole) is a known or presumed metabolite of the following synthetic cannabinoid(s): MMB-CHMICA; MDMB-CHMICA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
4-carboxy-CUMYL-BINACA	ng/mL	4-carboxy-CUMYL-BINACA (CUMYL-BUTINACA N-
		is a known or presumed metabolite of the following synthetic cannabinoid(s): 4-cyano-CUMYL-BINACA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
4-carboxy-AMB-PINACA	ng/mL	4-carboxy-AMB-PINACA (AB-PINACA N-pentanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): AMB-PINACA(AB-PINACA).
		It may also be a metabolite of other synthetic cannabinoids with similar structures. Compounds known to interfere with this substance: 5-fluoro-PIC-ACID (5-Fluoro-PB-22 3-Carboxyindole).



Compound Name	Units	Reference Comment
5-fluoro-PINAC-ACID	ng/mL	5-fluoro-PINAC-ACID (5F-NPB-22-Carboxyindazole) is a known or presumed metabolite of the following synthetic cannabinoid(s): 5-fluoro-EDMB-PINACA; 5-fluoro-MDMB-PINACA (5F-ADB); 5-fluoro-EMB-PINACA (5F-AEB); 5-fluoro-MMB-PINACA (5-fluoro AMB); 5-fluoro-QU-PINAC (5F-NPB-22).
		It may also be a metabolite of other synthetic cannabinoids with similar structures. Compounds known to interfere with this substance: 5-fluoro-PICA 3,3-dimethylbutanoic acid.
CHMINACA 3,3- dimethylbutanoic acid	ng/mL	CHMINACA 3,3-dimethylbutanoic acid (ADB-CHMINACA 3,3-dimethyl-butanoic acid, MAB-CHMINACA Metabolite) is a known or presumed metabolite of the following synthetic cannabinoid(s): ADMB-CHMINACA (ADB-CHMINACA; MAB-CHMINACA); MDMB-CHMINACA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
5-fluoro-PINACA 3- methylbutanoic acid	ng/mL	5-fluoro-PINACA 3-methylbutanoic acid (5F-AMB 3-methyl-butanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): 5-fluoro-MMB-PINACA (5-fluoro AMB); 5-fluoro-EMB-PINACA (5F-AEB).
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
5-fluoro-PINACA 3,3- dimethylbutanoic acid	ng/mL	5-fluoro-PINACA 3,3-dimethylbutanoic acid (5F-ADB 3,3-dimethyl-butanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): 5-fluoro-MDMB-PINACA (5F-ADB); 5-fluoro-EDMB-PINACA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.



Compound Name	Units	Reference Comment
FUBINACA 3-methylbutanoi acid	ic ng/mL	FUBINACA 3-methylbutanoic acid (FUB-AMB 3-methyl-butanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): AMB-FUBINACA (AB-FUBINACA); MMB-FUBINACA (FUB- AMB); EMB-FUBINACA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
FUBINACA 3,3- dimethylbutanoic acid	ng/mL	FUBINACA 3,3-dimethylbutanoic acid (MDMB-FUBINACA 3,3-dimethyl-butanoic acid; MDMB-FUBINACA M1) is a known or presumed metabolite of the following synthetic cannabinoid(s): MDMB-FUBINACA; ADMB-FUBINACA (ADB-FUBINACA).
		It may also be a metabolite of other synthetic cannabinoids with similar structures. Compounds known to interfere with this substance: Quetiapine.
9562U Synthetic Canr	nabinoid Metabolites Sc	reen - Expanded (2019 Scope), Urine (Forensic)
Summary of Changes:	Test Name was changed. Scope of Analysis was changed. 5-fluoro-PICA 3,3-dimethylbutanoic acid, CHMINACA-3-methylbutanoic acid, FUBICA 3,3-dimethylbutanoic acid, 5-fluoro-PIC-ACID, CHMIC-ACID, 4- carboxy-CUMYL-BINACA, 4-carboxy-AMB-PINACA, 5-fluoro-PINAC-ACID, CHMINACA 3,3-dimethylbutanoic acid, 5-fluoro-PINACA 3-methylbutanoic acid, 5-fluoro-PINACA 3,3-dimethylbutanoic acid, 5-fluoro-PINACA 3- methylbutanoic acid, FUBINACA 3,3-dimethylbutanoic acid, 4-carboxy-NA- PIM and FUBIC-ACID were added. JWH-018 N-pentanoic acid, UR-144 N-pentanoic acid, AKB48 N-pentanoic acid, AB-FUBINACA oxobutanoic acid, AB-CHMINACA 3-methyl-butanoic acid, PB-22 3-Carboxyindole, 5-Fluoro-PB-22 3-Carboxyindole, BB-22 3- Carboxyindole, ADB-PINACA N-pentanoic acid, AB-PINACA N-pentanoic acid, ADBICA N-pentanoic acid, ADB-CHMINACA 3,3-dimethyl-butanoic acid, 5F-AMB 3-methyl-butanoic acid, 5F-ADB 3,3-dimethyl-butanoic acid, FUB- AMB 3-methyl-butanoic acid and MDMB-FUBINACA 3,3-dimethyl-butanoic acid were removed.	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80307): 4-carboxy-NA-PIM, FUBIC-ACID, 5-fluoro-PICA 3,3- dimethylbutanoic acid, CHMINACA-3-methylbutanoic acid, FUBICA 3,3- dimethylbutanoic acid, 5-fluoro-PIC-ACID, CHMIC-ACID, 4-carboxy-CUMYL- BINACA, 4-carboxy-AMB-PINACA, 5-fluoro-PINAC-ACID, CHMINACA 3,3- dimethylbutanoic acid, 5-fluoro-PINACA 3-methylbutanoic acid, 5-fluoro-PINACA 3,3- dimethylbutanoic acid, FUBINACA 3-methylbutanoic acid, FUBINACA 3,3- dimethylbutanoic acid	



Test Changes

Compound Name	Units	Reference Comment
4-carboxy-NA-PIM	ng/mL	
FUBIC-ACID	ng/mL	
5-fluoro-PICA 3,3-	ng/mL	
dimethylbutanoic acid		
CHMINACA-3-methylbutanoic	ng/mL	
acid		
FUBICA 3,3-dimethylbutanoic	ng/mL	
acid		
5-fluoro-PIC-ACID	ng/mL	
CHMIC-ACID	ng/mL	
4-carboxy-CUMYL-BINACA	ng/mL	
4-carboxy-AMB-PINACA	ng/mL	
5-fluoro-PINAC-ACID	ng/mL	
CHMINACA 3,3-	ng/mL	
dimethylbutanoic acid		
5-fluoro-PINACA 3-	ng/mL	
methylbutanoic acid		
5-fluoro-PINACA 3,3-	ng/mL	
dimethylbutanoic acid		
FUBINACA 3-methylbutanoic	ng/mL	
acid		
FUBINACA 3,3-	ng/mL	
dimethylbutanoic acid		
283U Synthetic Cannabin	oid Metabolite	es-Expanded (Qualitative) (2019 Scope), Urine

Summary of Changes: Test Name was changed.

Scope of Analysis was changed.

5-fluoro-PICA 3,3-dimethylbutanoic acid, CHMINACA-3-methylbutanoic acid, FUBICA 3,3-dimethylbutanoic acid, 5-fluoro-PIC-ACID, CHMIC-ACID, 4carboxy-CUMYL-BINACA, 4-carboxy-AMB-PINACA, 5-fluoro-PINAC-ACID, CHMINACA 3,3-dimethylbutanoic acid, 5-fluoro-PINACA 3-methylbutanoic acid, 5-fluoro-PINACA 3,3-dimethylbutanoic acid, FUBINACA 3methylbutanoic acid, FUBINACA 3,3-dimethylbutanoic acid, 4-carboxy-NA-PIM and FUBIC-ACID were added. JWH-018 N-pentanoic acid, UR-144 N-pentanoic acid, AKB48 N-pentanoic acid, AB-FUBINACA oxobutanoic acid, AB-CHMINACA 3-methyl-butanoic acid, PB-22 3-Carboxyindole, 5-Fluoro-PB-22 3-Carboxyindole, BB-22 3-Carboxyindole, ADB-PINACA N-pentanoic acid, AB-PINACA N-pentanoic acid, ADBICA N-pentanoic acid, ADB-CHMINACA 3,3-dimethyl-butanoic acid, 5F-AMB 3-methyl-butanoic acid, 5F-ADB 3,3-dimethyl-butanoic acid, FUB-AMB 3-methyl-butanoic acid and MDMB-FUBINACA 3,3-dimethyl-butanoic acid were removed.



Test Changes		
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80352): 4-c dimethylbutanoic acid, 6 dimethylbutanoic acid, 5 BINACA, 4-carboxy-AM dimethylbutanoic acid, 5 dimethylbutanoic acid, 7 dimethylbutanoic acid	carboxy-NA-PIM, FUBIC-ACID, 5-fluoro-PICA 3,3- CHMINACA-3-methylbutanoic acid, FUBICA 3,3- 5-fluoro-PIC-ACID, CHMIC-ACID, 4-carboxy-CUMYL- IB-PINACA, 5-fluoro-PINAC-ACID, CHMINACA 3,3- 5-fluoro-PINACA 3-methylbutanoic acid, 5-fluoro-PINACA 3,3- FUBINACA 3-methylbutanoic acid, FUBINACA 3,3-
Compound Name	Units	Reference Comment
4-carboxy-NA-PIM	ng/mL	4-carboxy-NA-PIM (JWH-018 N-pentanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): NA-PIM (JWH-18).
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
FUBIC-ACID	ng/mL	FUBIC-ACID (FUB-PB-22-Carboxyindole) is a known or presumed metabolite of the following synthetic cannabinoid(s): ADMB-FUBICA (ADB-FUBICA); NA-FUBIM (FUB-JWH-18); NA-FUBIC (FDU-PB-22); MDMB-FUBICA; MMB-FUBICA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
5-fluoro-PICA 3,3- dimethylbutanoic acid	ng/mL	5-fluoro-PICA 3,3-dimethylbutanoic acid is a known or presumed metabolite of the following synthetic cannabinoid(s): 5-fluoro-MDMB-PICA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
CHMINACA-3-methylbutanc acid	ic ng/mL	CHMINACA-3-methylbutanoic acid (AB-CHMINACA 3-methyl-butanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): AMB-CHMINACA (AB-CHMINACA); MMB-CHMINACA (MA-CHMINACA).
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
FUBICA 3,3-dimethylbutano acid	ic ng/mL	FUBICA 3,3-dimethylbutanoic acid is a known or presumed metabolite of the following synthetic cannabinoid(s): ADMB-FUBICA (ADB-FUBICA); MDMB-FUBICA (5-fluoro AMB).
		It may also be a metabolite of other synthetic cannabinoids with similar structures.



Compound Name	Units	Reference Comment
5-fluoro-PIC-ACID	ng/mL	5-fluoro-PIC-ACID (5-Fluoro-PB-22 3-Carboxyindole) is a known or presumed metabolite of the following synthetic cannabinoid(s): 5-fluoro-MDMB-PICA; 5-fluoro-NA-PIC (NM-221).
		It may also be a metabolite of other synthetic cannabinoids with similar structures. Compounds known to interfere with this substance: 5-fluoro-PICA 3,3-dimethylbutanoic acid.
CHMIC-ACID	ng/mL	CHMIC-ACID (BB-22 3-Carboxyindole) is a known or presumed metabolite of the following synthetic cannabinoid(s): MMB-CHMICA; MDMB-CHMICA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
4-carboxy-CUMYL-BINACA	ng/mL	4-carboxy-CUMYL-BINACA (CUMYL-BUTINACA N- Butanoic Acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): 4-cyano-CUMYL-BINACA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
4-carboxy-AMB-PINACA	ng/mL	4-carboxy-AMB-PINACA (AB-PINACA N-pentanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): AMB-PINACA(AB-PINACA).
		It may also be a metabolite of other synthetic cannabinoids with similar structures. Compounds known to interfere with this substance: 5-fluoro-PIC-ACID (5-Fluoro-PB-22 3-Carboxyindole).
5-fluoro-PINAC-ACID	ng/mL	5-fluoro-PINAC-ACID (5F-NPB-22-Carboxyindazole) is a known or presumed metabolite of the following synthetic cannabinoid(s): 5-fluoro-EDMB-PINACA; 5-fluoro-MDMB-PINACA (5F-ADB); 5-fluoro-EMB-PINACA (5F-AEB); 5-fluoro-MMB-PINACA (5-fluoro AMB); 5-fluoro-QU-PINAC (5F-NPB-22).
		It may also be a metabolite of other synthetic cannabinoids with similar structures.



Compound Name	Units	Reference Comment
CHMINACA 3,3- dimethylbutanoic acid	ng/mL	CHMINACA 3,3-dimethylbutanoic acid (ADB-CHMINACA 3,3-dimethyl-butanoic acid, MAB-CHMINACA Metabolite) is a known or presumed metabolite of the following synthetic cannabinoid(s): ADMB-CHMINACA (ADB-CHMINACA; MAB-CHMINACA); MDMB-CHMINACA.
		cannabinoids with similar structures.
5-fluoro-PINACA 3- methylbutanoic acid	ng/mL	5-fluoro-PINACA 3-methylbutanoic acid (5F-AMB 3-methyl-butanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): 5-fluoro-MMB-PINACA (5-fluoro AMB); 5-fluoro-EMB-PINACA (5F-AEB).
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
5-fluoro-PINACA 3,3- dimethylbutanoic acid	ng/mL	5-fluoro-PINACA 3,3-dimethylbutanoic acid (5F-ADB 3,3-dimethyl-butanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): 5-fluoro-MDMB-PINACA (5F-ADB); 5-fluoro-EDMB-PINACA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
FUBINACA 3-methylbutanoic acid	ng/mL	FUBINACA 3-methylbutanoic acid (FUB-AMB 3-methyl-butanoic acid) is a known or presumed metabolite of the following synthetic cannabinoid(s): AMB-FUBINACA (AB-FUBINACA); MMB-FUBINACA (FUB- AMB); EMB-FUBINACA.
		It may also be a metabolite of other synthetic cannabinoids with similar structures.
FUBINACA 3,3- dimethylbutanoic acid	ng/mL	FUBINACA 3,3-dimethylbutanoic acid (MDMB-FUBINACA 3,3-dimethyl-butanoic acid; MDMB-FUBINACA M1) is a known or presumed metabolite of the following synthetic cannabinoid(s): MDMB-FUBINACA; ADMB-FUBINACA (ADB-FUBINACA).
		It may also be a metabolite of other synthetic cannabinoids with similar structures. Compounds known to interfere with this substance: Quetiapine.



Test Changes

4759SP Valproic Acid	- Unbound and Total, Serum/Pl	asma
Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. Valproic Acid - Unbound was added. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80165), LC-MS/MS (80164)] Valproic Acid - Free was removed.	
Specimen Requirements:	2 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-	free)
Light Protection:	Not Required	
Special Handling: Rejection Criteria:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Polymer gel separation tube (SST or PST).	
Stability: Scope of Analysis: Method (CPT Code)	Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 3 month(s) LC-MS/MS (80165): Valproic Ad LC-MS/MS (80164): Valproic Ad	cid - Unbound cid - Total
Compound Name	Units	Reference Comment
Valproic Acid - Unbound	mcg/mL	The unbound fraction of valproic acid ranges from 10% at 40 mcg/mL to 18.5% at 130 mcg/mL.
Valproic Acid - Total	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with valproic acid: 50-100 mcg/mL
52162B Valproic Acid	Confirmation, Blood (CSA)	
Summary of Changes:	Specimen Requirements were	changed.

Specimen Requirements (Specimen Container) were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80164)]



Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80164): Valproic Acid

Compound Name	Units	Reference Comment
Valproic Acid	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with valproic acid: 50-100 mcg/mL The blood/plasma concentration ratio for valproic acid is approximately 0.5.

52162FL	Valproic Acid	Confirmation.	Fluid ((CSA)	
	Taipi olo / lola	oonnaaton,	i iaia (00/1	

Summary of Changes:	Specimen Requirements were changed. Methods/CPT Codes were changed [LC-MS/MS (80164)]
Specimen Requirements: Transport Temperature: Specimen Container:	2 mL Fluid Refrigerated Plastic container (preservative-free) Not Required
Special Handling: Rejection Criteria: Scope of Analysis: Method (CPT Code)	None None LC-MS/MS (80164): Valproic Acid
52162SP Valproic Acid (Confirmation, Serum/Plasma (CSA)

Summary of Changes: Specimen Requirements (Special Handling) were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80164)]





Specimen Requirements:	1 mL Serum or Plasma	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-free)	
Light Protection:	Not Required	
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.	
Rejection Criteria:	Polymer gel separation tube (S	ST or PST).
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80164): Valproic A	cid
Compound Name	Units	Reference Comment
Valproic Acid	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with valproic acid: 50-100 mcg/mL
52162TI Valproic Acid	Confirmation, Tissue (CSA)	
Summary of Changes:	Methods/CPT Codes were cha	nged [LC-MS/MS (80164)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80164): Valproic Acid	
52162U Valproic Acid	Confirmation, Urine (CSA)	
Summary of Changes:	Specimen Requirements (Spec Methods/CPT Codes were char	imen Container) were changed. nged [LC-MS/MS (80164)]
Specimen Requirements:	1 mL Urine	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-	free)
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80164): Valproic A	cid
9552B Valproic Acid	Screen (Add-On), Blood (Forer	nsic) (CSA)
Summary of Changes:	Specimen Requirements were Specimen Requirements (Spec Reference Comment was chan Methods/CPT Codes were cha	changed. imen Container) were changed. ged. nged [LC-MS/MS (80307)]



Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80307): Valproic Acid

Compound Name	Units	Reference Comment
Valproic Acid	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with valproic acid: 50-100 mcg/mL The blood/plasma concentration ratio for valproic acid is approximately 0.5.

9552FL Valproic Acid	Screen (Add-On), Fluid (Forensic) (CSA)
Summary of Changes:	Specimen Requirements were changed. Methods/CPT Codes were changed [LC-MS/MS (80307)]
Specimen Requirements:	3 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80307): Valproic Acid
9552SP Valproic Acid	Screen (Add-On), Serum/Plasma (Forensic) (CSA)
Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Special Handling) were changed. Reference Comment was changed.

Methods/CPT Codes were changed [LC-MS/MS (80307)]





Specimen Requirements:	1 mL Serum or Plasma		
Transport Temperature:	Refrigerated		
Specimen Container:	Plastic container (preservative-free)		
Light Protection:	Not Required		
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.		
Rejection Criteria:	Polymer gel separation tube (SST or PST).		
Method (CPT Code)	LC-MS/MS (80307): Valpro	DIC ACID	
Compound Name	Units	Reference Comment	
Valproic Acid	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with valproic acid: 50-100 mcg/mL	
9552TI Valproic Acid	Screen (Add-On), Tissue (I	Forensic) (CSA)	
Summary of Changes:	Methods/CPT Codes were	changed [LC-MS/MS (80307)]	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80307): Valproic Acid		
9552U Valproic Acid	Screen (Add-On), Urine (Fo	orensic) (CSA)	
Summary of Changes:	Specimen Requirements w Specimen Requirements (Methods/CPT Codes were	/ere changed. Specimen Container) were changed. changed [LC-MS/MS (80307)]	
Specimen Requirements:	1 mL Urine		
Transport Temperature:	Refrigerated		
Specimen Container:	Plastic container (preservative-free)		
Light Protection:	Not Required		
Special Handling:	None		
Rejection Criteria:	None		
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80307): Valproic Acid		
4757B Valproic Acid,	Blood		
Summary of Changes:	Specimen Requirements w Specimen Requirements (S Reference Comment was o Methods/CPT Codes were	vere changed. Specimen Container) were changed. changed. changed [LC-MS/MS (80164)]	



Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80164): Valproic Acid

ompound Name	Units	Reference Comment
Iproic Acid	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with valproic acid: 50-100 mcg/mL The blood/plasma concentration ratio for valproic acid is approximately 0.5
	mcg/mL	anticonvulsant therapy with valproic acid: 50-100 mc The blood/plasma concentration ratio for valproic acid is approximately 0.5.

4757FL Valproic Acid	, Fluid
Summary of Changes:	Specimen Requirements were changed. Methods/CPT Codes were changed [LC-MS/MS (80164)]
Specimen Requirements:	2 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80164): Valproic Acid
4757SP Valproic Acid	, Serum/Plasma
Summary of Changes:	Specimen Requirements (Special Handling) were changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80164)]





Specimen Requirements:	1 mL Serum or Plasma		
Transport Temperature:	Refrigerated		
Specimen Container:	Plastic container (preservative-free)		
Light Protection:	Not Required		
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.		
Rejection Criteria:	Polymer gel separation tube (S	ST or PST).	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80164): Valproic Ac	cid	
Compound Name	Units	Reference Comment	
Valproic Acid	mcg/mL	Recommended serum concentration range during anticonvulsant therapy with valproic acid: 50-100 mcg/mL	
4757TI Valproic Acid,	Tissue		
Summary of Changes:	Methods/CPT Codes were char	nged [LC-MS/MS (80164)]	
Scope of Analysis:	LC-MS/MS (80164): Valproic Acid		
Wethod (CFT Code)			
4761SP Valproic Acid,	Unbound, Serum/Plasma		
4761SP Valproic Acid, Summary of Changes:	Unbound, Serum/Plasma Test Name was changed. Specimen Requirements were of Scope of Analysis was changed Valproic Acid - Unbound was ac Methods/CPT Codes were char Valproic Acid - Free was remove	changed. I. Ided. nged [LC-MS/MS (80165)] ed.	
4761SP Valproic Acid, Summary of Changes: Specimen Requirements:	Unbound, Serum/Plasma Test Name was changed. Specimen Requirements were of Scope of Analysis was changed Valproic Acid - Unbound was ad Methods/CPT Codes were char Valproic Acid - Free was removed 2 mL Serum or Plasma	changed. 1. dded. nged [LC-MS/MS (80165)] ed.	
4761SP Valproic Acid, Summary of Changes: Specimen Requirements: Transport Temperature:	Unbound, Serum/Plasma Test Name was changed. Specimen Requirements were of Scope of Analysis was changed Valproic Acid - Unbound was ad Methods/CPT Codes were char Valproic Acid - Free was removed 2 mL Serum or Plasma Refrigerated	changed. I. Ided. nged [LC-MS/MS (80165)] ed.	
4761SP Valproic Acid, Summary of Changes: Specimen Requirements: Transport Temperature: Specimen Container:	Unbound, Serum/Plasma Test Name was changed. Specimen Requirements were of Scope of Analysis was changed Valproic Acid - Unbound was ac Methods/CPT Codes were char Valproic Acid - Free was remove 2 mL Serum or Plasma Refrigerated Plastic container (preservative-t	changed. 1. dded. nged [LC-MS/MS (80165)] ed.	
4761SP Valproic Acid, Summary of Changes: Specimen Requirements: Transport Temperature: Specimen Container: Light Protection:	Unbound, Serum/Plasma Test Name was changed. Specimen Requirements were of Scope of Analysis was changed Valproic Acid - Unbound was ad Methods/CPT Codes were char Valproic Acid - Free was remove 2 mL Serum or Plasma Refrigerated Plastic container (preservative-to Not Required	changed. J. Jded. nged [LC-MS/MS (80165)] ed.	
4761SP Valproic Acid, Summary of Changes: Specimen Requirements: Transport Temperature: Specimen Container: Light Protection: Special Handling:	Unbound, Serum/Plasma Test Name was changed. Specimen Requirements were of Scope of Analysis was changed Valproic Acid - Unbound was ac Methods/CPT Codes were char Valproic Acid - Free was remove 2 mL Serum or Plasma Refrigerated Plastic container (preservative-f Not Required Serum: Collect sample in Red to Plasma: Collect sample in Lave Promptly centrifuge and separa using approved guidelines.	changed. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	
4761SP Valproic Acid, Summary of Changes: Specimen Requirements: Transport Temperature: Specimen Container: Light Protection: Special Handling: Rejection Criteria:	Unbound, Serum/Plasma Test Name was changed. Specimen Requirements were of Scope of Analysis was changed Valproic Acid - Unbound was ac Methods/CPT Codes were char Valproic Acid - Free was remove 2 mL Serum or Plasma Refrigerated Plastic container (preservative-th Not Required Serum: Collect sample in Red th Plasma: Collect sample in Lave Promptly centrifuge and separa using approved guidelines. Polymer gel separation tube (St	changed. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	



Compound Name	Units	Reference Comment
Valproic Acid - Unbound	mcg/mL The unbound fraction of valproic acid ranges from 10% at 40 mcg/mL to 18.5% at 130 mcg/mL.	
4757U Valproic Acid,	Urine	
Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Methods/CPT Codes were changed [LC-MS/MS (80164)]	
Specimen Requirements:	1 mL Urine	
Transport Temperature:	Refrigerated	
Specimen Container:	Plastic container (preservative-free)	
Light Protection:	Not Required	
Special Handling:	None	
Rejection Criteria:	None	
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80164): Valproic Ad	sid



Discontinued Tests

Test Code	Test Name	Alternative Test
52020FL	Chlorzoxazone Confirmation, Fluid	No Alternate Tests Available
52020TI	Chlorzoxazone Confirmation, Tissue	No Alternate Tests Available
52020U	Chlorzoxazone Confirmation, Urine	No Alternate Tests Available
1255U	Chlorzoxazone, Urine	1255SP - Chlorzoxazone, Serum/Plasma
52069B	Mephenytoin and Metabolite Confirmation, Blood	No Alternate Tests Available
52069FL	Mephenytoin and Metabolite Confirmation, Fluid	No Alternate Tests Available
52069SP	Mephenytoin and Metabolite Confirmation, Serum/Plasma	No Alternate Tests Available
52069TI	Mephenytoin and Metabolite Confirmation, Tissue	No Alternate Tests Available
2620SP	Mephenytoin and Metabolite, Serum/Plasma	No Alternate Tests Available
52070B	Mephobarbital and Metabolite Confirmation, Blood	No Alternate Tests Available
52070FL	Mephobarbital and Metabolite Confirmation, Fluid	No Alternate Tests Available
52070SP	Mephobarbital and Metabolite Confirmation, Serum/Plasma	No Alternate Tests Available
52070TI	Mephobarbital and Metabolite Confirmation, Tissue	No Alternate Tests Available
2630B	Mephobarbital and Metabolite, Blood	3580B - Phenobarbital, Blood
2630SP	Mephobarbital and Metabolite, Serum/Plasma	3580SP - Phenobarbital, Serum/Plasma
5644SP	Methsuximide as Metabolite Confirmation, Serum/Plasma	No Alternate Tests Available
9336SP	Methsuximide as Metabolite Screen,	2950SP - Methsuximide as Metabolite,
	Serum/Plasma	Serum/Plasma
3380B	Pemoline, Blood	No Alternate Tests Available
3380SP	Pemoline, Serum/Plasma	No Alternate Tests Available
3751SP	Phenytoin - Total, Serum/Plasma	3743SP - Phenytoin, Serum/Plasma
5673B	Phenytoin Confirmation, Blood	No Alternate Tests Available
5673FL	Phenytoin Confirmation, Fluid	No Alternate Tests Available
5673SP	Phenytoin Confirmation, Serum/Plasma	No Alternate Tests Available
9239B	Phenytoin Screen, Blood	3743B - Phenytoin, Blood
9239FL	Phenytoin Screen, Fluid	3743FL - Phenytoin, Fluid
9239SP	Phenytoin Screen, Serum/Plasma	3743SP - Phenytoin, Serum/Plasma
4760SP	Valproic Acid, Serum/Plasma	4757SP - Valproic Acid, Serum/Plasma